Study design and participants
allergic, palpitations, cancer pain, traumatic pain, pain, dizziness, allergies, drug abuse, nausea, vomiting
ALLERGIES
Our trial was a randomized, double‐blind, placebo‐controlled, longitudinal superiority trial performed at one tertiary hospital in Shanghai, China (Xinhua Hospital, affiliated with Shanghai Jiaotong University School of Medicine). Eligible participants were 18–80 years oldPatients who were allergic to L‐TAMS or could not tolerate normal oral doses (suffering side effects such as nausea, vomiting, dizziness, palpitations or other obvious discomfort) were excluded; patients who were predisposed to allergies were also excluded, as were those with past or present drug abuse or drug addiction. Other exclusion criteria included women who were breastfeeding or pregnant, patients (men included) who were trying to conceive within 1 month after this trial, patients who had participated in any drug trial (including trials of L‐TAMS) within 3 months prior to this trial, and those who had significant traumatic pain or postoperative incision pain in addition to cancer pain.